Aurobindo receives FDA approvals for high blood pressure, HIV products

By Lisa Kerner

Erie, Pa., March 16 - Aurobindo Pharma Ltd. said the Food and Drug Administration approved the company's Lisinopril and Hydrochlorothiazide tablets, 10/12.5 mg, 20/12.5 mg, and 20/25 mg, the generic version of Merck's Prinzide tables, for high blood pressure.

Aurobindo also received FDA approval for its New Drug Application for Lamivudine 150 mg/Zidovudine 300 mg Fixed-Dose Tablets co-packed with Efavirenz 600 mg Tablets for the treatment of HIV-1 infection.

The Lamivudine/zidovudine fixed dose combination tablets are a version of Combivir tablets manufactured by GlaxoSmithKline, and the Efavirenz tablets are a version of Bristol Myers-Squibb's Sustiva tablets.

Aurobindo, based at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.